CRYSTAL LAKE, Ill. — AptarGroup, Inc. announced that its Unidose (UDS) Powder Nasal Spray System is being used in ENA Respiratory’s Phase II clinical study of INNA-051, an investigational nasal spray designed to help protect against symptomatic viral respiratory infections.
The collaboration highlights the growing role of intranasal delivery technologies in the development of non-vaccine approaches to respiratory disease prevention. ENA Respiratory, a clinical-stage pharmaceutical company, recently began dosing participants in the Phase II trial, which is evaluating the safety, tolerability, and potential effectiveness of the once-weekly nasal spray in adults at increased risk of exposure to respiratory viruses.
The community-based study is designed to assess whether INNA-051 can help reduce the burden of symptomatic respiratory viral illness.
Aptar’s UDS powder nasal delivery system is engineered to deliver a single, precise dose of dry powder with consistent intranasal performance, supporting reliable administration in clinical settings. The system is designed for ease of use and is suited for nasal powder formulations that may benefit from improved stability.
The device will be housed in Aptar CSP Technologies’ container closure system, which incorporates 3-Phase Activ-Polymer technology to protect the formulation from moisture. The system also includes features intended to prevent premature actuation during handling, helping ensure consistent access to the medication.
“Aptar Pharma is proud to support ENA Respiratory in the clinical development of INNA-051 through the use of our UDS powder nasal delivery system,” said Alex Theodorakis, President, Aptar Pharma Prescription. “By combining reliable intranasal delivery technologies with comprehensive technical and regulatory expertise, we help our partners advance innovative therapies intended to address unmet needs in respiratory health.” (Source: IANS)
